Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 16 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

31%

5 trials in Phase 3/4

Results Transparency

0%

0 of 11 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
8(50.0%)
Phase 3
5(31.3%)
Phase 2
2(12.5%)
N/A
1(6.3%)
16Total
Phase 1(8)
Phase 3(5)
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials
NCT03038802Phase 1Not Yet Recruiting

A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection

Role: lead

NCT05807035Phase 1Recruiting

Autologous Tumour Vaccine Trial

Role: lead

NCT06355232Phase 1Recruiting

Covid-19 and Influenza Oral Vaccine Study

Role: lead

NCT05542862Phase 3Completed

Booster Study of SpikoGen COVID-19 Vaccine

Role: lead

NCT05279456Phase 3Completed

A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)

Role: lead

NCT05148871Phase 2Active Not Recruiting

Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine

Role: lead

NCT05285384Not ApplicableCompleted

Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine

Role: collaborator

NCT05231590Phase 3Completed

Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years

Role: collaborator

NCT05175625Phase 3Completed

Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine

Role: collaborator

NCT04944368Phase 2Completed

Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

Role: collaborator

NCT05005559Phase 3Completed

Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

Role: collaborator

NCT04453852Phase 1Completed

Monovalent Recombinant COVID19 Vaccine

Role: lead

NCT03066986Phase 1Unknown

Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant (Jumpvax)

Role: collaborator

NCT03038776Phase 1Completed

Recombinant H7 Hemagglutinin Influenza Vaccine Trial

Role: lead

NCT01951677Phase 1Completed

Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine

Role: lead

NCT02335164Phase 1Completed

A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults

Role: lead

All 16 trials loaded